246 related articles for article (PubMed ID: 15843547)
1. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.
Shurin GV; Ferris RL; Tourkova IL; Perez L; Lokshin A; Balkir L; Collins B; Chatta GS; Shurin MR
J Immunol; 2005 May; 174(9):5490-8. PubMed ID: 15843547
[TBL] [Abstract][Full Text] [Related]
2. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
Wang H; Nan S; Wang Y; Xu C
J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
[TBL] [Abstract][Full Text] [Related]
3. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma.
Miyamoto C; Maehata Y; Motohashi K; Ozawa S; Ikoma T; Hidaka K; Wada-Takahashi S; Takahashi SS; Yoshino F; Yoshida A; Kubota E; Hata R; Lee MC
Biomed Res; 2014; 35(6):381-8. PubMed ID: 25743344
[TBL] [Abstract][Full Text] [Related]
4. Expression of CXCL14 and its anticancer role in breast cancer.
Gu XL; Ou ZL; Lin FJ; Yang XL; Luo JM; Shen ZZ; Shao ZM
Breast Cancer Res Treat; 2012 Oct; 135(3):725-35. PubMed ID: 22910931
[TBL] [Abstract][Full Text] [Related]
5. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Ozawa S; Kato Y; Ito S; Komori R; Shiiki N; Tsukinoki K; Ozono S; Maehata Y; Taguchi T; Imagawa-Ishiguro Y; Tsukuda M; Kubota E; Hata R
Cancer Sci; 2009 Nov; 100(11):2202-9. PubMed ID: 19673887
[TBL] [Abstract][Full Text] [Related]
6. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell transplants. [corrected].
Izukuri K; Suzuki K; Yajima N; Ozawa S; Ito S; Kubota E; Hata R
Transgenic Res; 2010 Dec; 19(6):1109-17. PubMed ID: 20333465
[TBL] [Abstract][Full Text] [Related]
7. Expression of tumour-suppressing chemokine BRAK/CXCL14 reduces cell migration rate of HSC-3 tongue carcinoma cells and stimulates attachment to collagen and formation of elongated focal adhesions in vitro.
Sato K; Ozawa S; Izukuri K; Kato Y; Hata R
Cell Biol Int; 2010 Apr; 34(5):513-22. PubMed ID: 20067447
[TBL] [Abstract][Full Text] [Related]
8. Expression of a chemokine BRAK/CXCL14 in oral floor carcinoma cells reduces the settlement rate of the cells and suppresses their proliferation in vivo.
Ito S; Ozawa S; Ikoma T; Yajima N; Kiyono T; Hata R
Biomed Res; 2010 Jun; 31(3):199-206. PubMed ID: 20622470
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of proximal promoter of gene for human BRAK/CXCL14, a tumor-suppressing chemokine.
Komori R; Ozawa S; Kato Y; Shinji H; Kimoto S; Hata R
Biomed Res; 2010 Apr; 31(2):123-31. PubMed ID: 20460740
[TBL] [Abstract][Full Text] [Related]
10. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
mBio; 2016 May; 7(3):. PubMed ID: 27143385
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species (ROS) reduce the expression of BRAK/CXCL14 in human head and neck squamous cell carcinoma cells.
Maehata Y; Ozawa S; Kobayashi K; Kato Y; Yoshino F; Miyamoto C; Izukuri K; Kubota E; Hata R; Lee MC
Free Radic Res; 2010 Aug; 44(8):913-24. PubMed ID: 20815772
[TBL] [Abstract][Full Text] [Related]
12. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells.
Shellenberger TD; Wang M; Gujrati M; Jayakumar A; Strieter RM; Burdick MD; Ioannides CG; Efferson CL; El-Naggar AK; Roberts D; Clayman GL; Frederick MJ
Cancer Res; 2004 Nov; 64(22):8262-70. PubMed ID: 15548693
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells.
Song EY; Shurin MR; Tourkova IL; Gutkin DW; Shurin GV
Cancer Res; 2010 Jun; 70(11):4394-401. PubMed ID: 20460540
[TBL] [Abstract][Full Text] [Related]
14. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy.
Starnes T; Rasila KK; Robertson MJ; Brahmi Z; Dahl R; Christopherson K; Hromas R
Exp Hematol; 2006 Aug; 34(8):1101-5. PubMed ID: 16863917
[TBL] [Abstract][Full Text] [Related]
15. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells.
Means TK; Hayashi F; Smith KD; Aderem A; Luster AD
J Immunol; 2003 May; 170(10):5165-75. PubMed ID: 12734364
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma.
Guan J; Weng J; Ren Q; Zhang C; Hu L; Deng W; Lu S; Dong X; Li W; Li Y; Wang W
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34870709
[TBL] [Abstract][Full Text] [Related]
17. Murine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues.
Meuter S; Schaerli P; Roos RS; Brandau O; Bösl MR; von Andrian UH; Moser B
Mol Cell Biol; 2007 Feb; 27(3):983-92. PubMed ID: 17130243
[TBL] [Abstract][Full Text] [Related]
18. BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo.
Vissers JL; Hartgers FC; Lindhout E; Figdor CG; Adema GJ
Eur J Immunol; 2001 May; 31(5):1544-9. PubMed ID: 11465112
[TBL] [Abstract][Full Text] [Related]
19. Constitutive expression of CXCL14 in healthy human and murine epithelial tissues.
Meuter S; Moser B
Cytokine; 2008 Nov; 44(2):248-55. PubMed ID: 18809336
[TBL] [Abstract][Full Text] [Related]
20. A New Strategy to Find Targets for Anticancer Therapy: Chemokine CXCL14/BRAK Is a Multifunctional Tumor Suppressor for Head and Neck Squamous Cell Carcinoma.
Hata R
ISRN Otolaryngol; 2012; 2012():797619. PubMed ID: 23762619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
